This is not the most recent version of the article. View current version (5 APR 2016)

Intervention Protocol

You have free access to this content

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia

  1. Kumar B Saha1,*,
  2. Stephanie Sampson2,
  3. Rashid U Zaman3

Editorial Group: Cochrane Schizophrenia Group

Published Online: 3 JUL 2013

DOI: 10.1002/14651858.CD010631


How to Cite

Saha KB, Sampson S, Zaman RU. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD010631. DOI: 10.1002/14651858.CD010631.

Author Information

  1. 1

    Leeds Partnership NHS Foundation Trust, Forensic Psychiatry, Leeds, UK

  2. 2

    The University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK

  3. 3

    Oxford Policy Management, Health Portfolio, Oxford, UK

*Kumar B Saha, Forensic Psychiatry, Leeds Partnership NHS Foundation Trust, Forensic Services, Newsam Centre, Seacroft Hospital, York Road, Leeds, LS14 6WB, UK. kbiswajits@yahoo.com.

Publication History

  1. Publication Status: New
  2. Published Online: 3 JUL 2013

SEARCH

This is not the most recent version of the article. View current version (05 APR 2016)

References

Additional references

Adams 2005
  • Adams C, Rathbone J, Thornley B, Clarke M, Borrill J, Kristian W, Awad AG. Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Medicine - http://www.biomedcentral.com/1741-7015/3/15 2005;3(15):1-7. [DOI: 10.1186/1741-7015-3-15]
Adams 2006
  • Adams CE, Tharyan P, Coutinho ES, Stroup TS. The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. British Journal of Psychiatry : the journal of mental science 2006; Vol. 189:391-2. [PUBMED: 17077426]
Adams 2007
Ahmed 2010
Almerie 2007
Altman 1996
Arana 2000
Bian 2008
  • Bian Q, Kato T, Monji A, Hashioka S, Mizoguchi Y, Horikawa H, et al. The effect of atypical antipsychotic drugs, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008;32(1):42-8.
Bland 1978
Bland 1997
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des indices d'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
Caccia 2010
Cincotta 2010
  • Cincotta SL, Rodefer JS. Emerging role of sertindole in the management of schizophrenia. Neuropsychiatric Disease and Treatment 2010;7:429-41.
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Delay 1952
  • Delay J, Deniker P. The treatment of psychosis in a derivative of the neuroleptic hibernotherapie method [google translate] [Le traitement des psychoses par une methode neuroleptique derivee de l'hibernotherapie]. In: Ossa PC editor(s). CR Congres des Medicins Alienistes et Neurologistes de France. Paris: Masson, 1952:479.
Divine 1992
Donner 2002
DSM-IV 1994
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 1994.
DSM-IV-TR 2000
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th Edition. Washington DC: American Psychiatric Association, 2000.
Egger 1997
Elbourne 2002
  • Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Furukawa 2006
  • Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
Gulliford 1999
  • Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hutton 2009
ICD-10 1992
  • World Health Organization. F-20. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: Divison of Mental Health, WHO, 1992:86-109.
Janssen 1988
  • Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. JPET 1988;244(2):685-93.
Kay 1986
  • Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
Kinon 1996
Kraeplin 1919
  • Kraeplin E. Dementia Praecox and Paraphrenia. Edinburgh: E&S Livingstone, 1919.
Laborit 1951
  • Laborit H, Huguenard P. Artificial hibernation by physical and pharmacodynamic means [Google translate] [L'Hibernation artificielle par Moyens pharmacodynamiques et physiques]. Presse Medicale 1951;59:1329.
Leucht 2005
Leucht 2005a
  • Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
Leucht 2007
  • Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotic drugs an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
Leucht 2008
Leucht 2009
Liu 2009
  • Liu X, De HS. Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007778; : CD007778]
Marshall 2000
  • Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
Mathews 2007
McGrath 2008
Meltzer 1989
Nadal 2001
Odejide 1982
  • Odejide AO, Ban TA. Psychotropic drug prescription pattern in a developing country (Nigeria). The need for an essential psychotherapeutic drug list. International Pharmacopsychiatry 1982;17:163-9.
Overall 1962
Risbood 2012
Rzewuska 1988
  • Rzewuska M. Sulpiride: the best known atypical, safe neuroleptic drug. Review of literature. Psychiatria Polska 1998 Sep-Oct;32(5):655-66. [PUBMED: 9921002]
Saha 2005
Schünemann 2008
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
Smith 2010
  • Smith TLL, Carter CW. Asenapine: a novel atypical antipsychotic agent for schizophrenia and bipolar I disorder. Journal of Pharmacy Technology 2010;26:352-61.
Takahashi 1999
Toren 1995
Turner 2007
  • Turner T. Chlorpromazine: unlocking psychosis. BMJ (Clinical research ed.) 2007;334 Suppl 1:s7. [PUBMED: 17204765]
Ukoumunne 1999
  • Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
WHO 2011
  • World Health Organization. WHO model list of essential medicines. WHO Essential Medicines List - http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf March 2011; Vol. 17th edition:30.
Xia 2009
  • Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
Yorston 2000
  • Yorston G, Pinney A. Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics. Psychiatric Bulletin 2000;24:130-2.
Zhang 1999